echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Seven-year follow-up analysis of auxiliary yew alcohol and quercetal monosupel test treatment nodule negative, human epidermal growth factor receptor 2 positive breast cancer

    J Clin Oncol: Seven-year follow-up analysis of auxiliary yew alcohol and quercetal monosupel test treatment nodule negative, human epidermal growth factor receptor 2 positive breast cancer

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The yew alcohol and quercetal monotomaadvance auxiliary tests are designed to solve the treatment problems of human patients with small epidermal growth factor receptor 2 (HER2) positive breast cancerThe main analysis of the auxiliary yew alcohol and qualmzumab test showed that the three-year disease-free survival (DFS) was 98.7%In the second-level analysis of this project, we reported longer-term and exploratory results to determine the biological characteristics of HER2-positive small tumors and genetic factors that may be susceptible to sequoia-induced peripheral neuropathy (TIPN)
    In this Phase II study, HER2-positive breast cancer patients with tumors of 3cm or less, negative nodules, 12 weeks of treatment with yew alcohol (80mg/m2) and quercetal monotobarbita, followed by curdy tolone monotorinoma for 9 monthsThe main endpoint is DFSNo recurrence interval (RFI), breast cancer-specific survival and total survival (OS) were also analyzedIn exploratory analysis, the intrinsic subtype is performed through PAM50 (Prosigna) and the recurrence risk score of archived tissue is calculated on the nCounter analysis systemThe GETypesurvey of TIPN was carried out
    Between October 2007 and September 2010, a total of 410 patients were enrolledAfter 6.5 years of median follow-up, there were 23 DFS incidents7 years DFS was 93% (95% CI, 90.4 to 96.2), of which 4 cases (1.0%) were relapsed in distance, 7 years OS was 95% (95% CI, 92.4 to 97.7), and 7 years RFI was 97.5% (95% CI, 95.9 to 99.1)The PAM50 analysis (n - 278) showed that the majority of tumors were HER2 enrichment (66%), followed by cavity B (14%), cavity A (13%) and substrate samples (8%)The genotybling (n s 230) found a single nucleotide polymorphism, rs3012437, associated with an increased risk of TIPN in patients with level 2 or higher TIPN (10.4%)
    In short, with the extension of follow-up time, auxiliary yew alcohol and querathrowma are associated with excellent long-term outcomesThe distribution of PAM50 inherent subtypes in small HER2-positive tumors was similar to that of larger tumors previously reported
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.